Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2022 Mar 4

PMID 35241912

Authors

Elidamar Nunes de Carvalho Lima

Ana Luiza Moraes Octaviano

Jose Roberto Castilho Piqueira

Ricardo Sobhie Diaz

Joao Francisco Justo

Affiliations

Soon will be listed here.

Abstract

Since December 2019, the world has faced an unprecedented pandemic crisis due to a new coronavirus disease, coronavirus disease-2019 (COVID-19), which has instigated intensive studies on prevention and treatment possibilities. Here, we investigate the relationships between the immune activation induced by three coronaviruses associated with recent outbreaks, with special attention to SARS-CoV-2, the causative agent of COVID-19, and the immune activation induced by carbon nanotubes (CNTs) to understand the points of convergence in immune induction and modulation. Evidence suggests that CNTs are among the most promising materials for use as immunotherapeutic agents. Therefore, this investigation explores new possibilities of effective immunotherapies for COVID-19. This study aimed to raise interest and knowledge about the use of CNTs as immunotherapeutic agents in coronavirus treatment. Thus, we summarize the most important immunological aspects of various coronavirus infections and describe key advances and challenges in using CNTs as immunotherapeutic agents against viral infections and the activation of the immune response induced by CNTs, which can shed light on the immunotherapeutic possibilities of CNTs.

Citing Articles

Effects of Carbon Nanomaterials and on Melanomas-Where Are We? Recent Updates.

de Carvalho Lima E, Barros Martins G, Diaz R, Schechter M, Piqueira J, Justo J Pharmaceutics. 2022; 14(10).

PMID: 36297440 PMC: 9607275. DOI: 10.3390/pharmaceutics14102004.

References

Hunt P . Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS. 2010; 5(2):189-93. PMC: 2917631. DOI: 10.1097/COH.0b013e32833647d9. View

Lee S, Channappanavar R, Kanneganti T . Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. Trends Immunol. 2020; 41(12):1083-1099. PMC: 7561287. DOI: 10.1016/j.it.2020.10.005. View

Parra J, Abad-Somovilla A, Mercader J, Taton T, Abad-Fuentes A . Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens. J Control Release. 2013; 170(2):242-51. DOI: 10.1016/j.jconrel.2013.05.019. View

Meher B, Wang Y . Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism. J Mol Graph Model. 2012; 38:430-45. PMC: 3508351. DOI: 10.1016/j.jmgm.2012.10.001. View

Khurana A, Anchi P, Allawadhi P, Kumar V, Sayed N, Packirisamy G . Superoxide dismutase mimetic nanoceria restrains cerulein induced acute pancreatitis. Nanomedicine (Lond). 2019; 14(14):1805-1825. DOI: 10.2217/nnm-2018-0318. View

Zhang Z, Wang B, Wan B, Yu L, Huang Q . Molecular dynamics study of carbon nanotube as a potential dual-functional inhibitor of HIV-1 integrase. Biochem Biophys Res Commun. 2013; 436(4):650-4. DOI: 10.1016/j.bbrc.2013.06.009. View

Hu X, Zhang Y, Ding T, Liu J, Zhao H . Multifunctional Gold Nanoparticles: A Novel Nanomaterial for Various Medical Applications and Biological Activities. Front Bioeng Biotechnol. 2020; 8:990. PMC: 7438450. DOI: 10.3389/fbioe.2020.00990. View

Aldinucci A, Turco A, Biagioli T, Toma F, Bani D, Guasti D . Carbon nanotube scaffolds instruct human dendritic cells: modulating immune responses by contacts at the nanoscale. Nano Lett. 2013; 13(12):6098-105. DOI: 10.1021/nl403396e. View

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

10.

Weiss S, Navas-Martin S . Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4):635-64. PMC: 1306801. DOI: 10.1128/MMBR.69.4.635-664.2005. View

11.

Kim Y, Aigerim A, Park U, Kim Y, Park H, Rhee J . Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability. Clin Infect Dis. 2020; 73(3):e550-e558. PMC: 7499518. DOI: 10.1093/cid/ciaa1345. View

12.

Maruyama K, Haniu H, Saito N, Matsuda Y, Tsukahara T, Kobayashi S . Endocytosis of Multiwalled Carbon Nanotubes in Bronchial Epithelial and Mesothelial Cells. Biomed Res Int. 2015; 2015:793186. PMC: 4450259. DOI: 10.1155/2015/793186. View

13.

Hassan H, Smyth L, Rubio N, Ratnasothy K, Wang J, Bansal S . Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. J Control Release. 2016; 225:205-16. PMC: 4778609. DOI: 10.1016/j.jconrel.2016.01.030. View

14.

Tea F, Stella A, Aggarwal A, Darley D, Pilli D, Vitale D . SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med. 2021; 18(7):e1003656. PMC: 8291755. DOI: 10.1371/journal.pmed.1003656. View

15.

Chue-Goncalves M, Pereira G, Faccin-Galhardi L, Kobayashi R, Nakazato G . Metal Nanoparticles against Viruses: Possibilities to Fight SARS-CoV-2. Nanomaterials (Basel). 2021; 11(11). PMC: 8618109. DOI: 10.3390/nano11113118. View

16.

de Carvalho Lima E, Diaz R, Justo J, Piqueira J . Advances and Perspectives in the Use of Carbon Nanotubes in Vaccine Development. Int J Nanomedicine. 2021; 16:5411-5435. PMC: 8367085. DOI: 10.2147/IJN.S314308. View

17.

Meng J, Duan J, Kong H, Li L, Wang C, Xie S . Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small. 2008; 4(9):1364-70. DOI: 10.1002/smll.200701059. View

18.

Nagaraju K, Reddy R, Reddy N . A review on protein functionalized carbon nanotubes. J Appl Biomater Funct Mater. 2015; 13(4):e301-12. DOI: 10.5301/jabfm.5000231. View

19.

Kotchey G, Zhao Y, Kagan V, Star A . Peroxidase-mediated biodegradation of carbon nanotubes in vitro and in vivo. Adv Drug Deliv Rev. 2013; 65(15):1921-32. PMC: 3855904. DOI: 10.1016/j.addr.2013.07.007. View

20.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View